You may have heard of Nexvax2, the “celiac vaccine” currently undergoing clinical trials in the US and around the world. (If you haven't, read this announcement.) It’s an exciting breakthrough, and one that has been more than 20 years in the making.
To offer some perspective, Bob Anderson, MBChB, PhD, FRACP, Chief Scientific Officer at ImmunsanT, Inc, the pharmaceutical company behind NexVax2, wrote an article explaining the history and research findings that led to the development of this potential vaccine.
To get a glimpse of the process that led scientists to where they are today, read:
Transforming celiac disease from a digestive disease to an immune disease: and restoring tolerance to gluten in celiac disease
Note: NFCA maintains the position that views and information presented on articles and websites we link to are those of the authors, and not necessarily those of NFCA.
CONNECT WITH NFCA
Advertise with us
© 2015 National Foundation for Celiac Awareness. All rights reserved.
The information found on this website is not intended to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical condition. We urge you to always seek the advice of your physician. There is no replacement for personal medical treatment and advice from your personal physician.
This site was last updated on
. If you have questions email the webmaster. celiac disease | celiac disease symptoms | gluten free products
This site complies with the HONcode standard for trustworthy health information: verify here.